NCT03391843View on ClinicalTrials.gov

Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Rectal Cancer Stage III
Interventions
DRUG

FOLFOXIRI+Cetuximab regimen

FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h +Cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle

Trial Locations (1)

2

Department of Radiation Oncology,Renji Hospital affiliated to Medical School, Shanghai Jiaotong University, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER